Tactile Systems Technology Inc.

• Total turnover: Rose by 0.3% compared to the previous year to $ 61.3 million.

• Lymphedema income: 3% dropped to 50.6 million US dollars compared to the previous year.

• Airway Clearance income: Rose by 22% to 10.7 million US dollars.

• Gross marge: Rose from 71% to 74% in the first quarter of 2024.

• Operating costs: Rose 8% to 49.9 million US dollars.

• Loss of business: Rose by 53% to 4.5 million US dollars.

• Net lust: Rose by 35% to $ 3 million or $ 0.13 per diluted share.

• Adapted EBITDA: Decreased to a loss of $ 0.3 million from an income of 1 million US dollars.

• Cash position: The quarter ended with 83.6 million US dollars at bar and cash equivalents.

• 2025 sales advice: Revised to $ 309 million to $ 315 million.

• 2025 expectation of lymphedema growth: 4% to 5% growth.

• 2025 Expectation of airway release: 20% to 23% growth.

• 2025 adapted EBITDA instructions: Probably 32 to 34 million US dollars.

Appearance date: May 05, 2025

You can find the complete copy of the earnings call in the complete earnings call.

• Total turnover rose by 0.3% to USD 61.3 million compared to the previous year, whereby the sales of respiratory release increased a significant increase in respiratory release.

• The gross margins improved by 290 basic points compared to the year, which indicates improvements in cost management and product design.

• The company ended the quarter with a strong cash position of USD 83.6 million, although a repurchase of shares has decreased by USD 10.7 million.

• The introduction of the Salesforce CRM module is expected to improve sales efficiency and data-controlled decision-making.

• Stark growth and introduction of the NIMBL product that exceeds the broader growth of the market for lymphedema.

• The sales of lymphedema business lines decreased by 3% compared to the previous year, which was affected by empty works and lower sales productivity.

• The adapted EBITDA decreased by 125% compared to the previous year due to planned investments in technology and order processes.

• The transition to the new Salesforce CRM module has temporarily influenced sales productivity more than expected.

• Operating costs rose by 8% to $ 49.9 million, which is due to strategic technology investments.

• The net loss rose by 35% to $ 3 million or $ 0.13 per diluted share compared to the previous year.

Q: What assumptions are taken into account for sales advice for the year, especially if you approach the fourth quarter? A: Elaine Birkemeyer, Chief Financial Officer, explained that the instructions into account the speed of setting planned sales functions and sales employees with the new CRM tool. The success of the parachute rollout and its expansion to Flexitouch as well as improvements to the back office efficiency are also factors. The instructions implied a sequential growth pattern, whereby the Q3 is expected to have low double -digit growth and Q4 similar to typical growth patterns.